On November 4, 2021, HGPI held the first meeting of Working Group 5 on vaccine research and development for “Next Actions for the Development and Implementation of Immunization and Vaccination Policies.” 

During this meeting, the members deepened their discussion on topics such as the issues in Japan’s vaccine R&D pipeline that were highlighted during the Coronavirus pandemic and the establishment of R&D pipelines in non-emergency situations for the 100 Days Mission, which aims to develop a vaccine within 100 days after the confirmation of a new infectious disease was agreed upon by the G7. There were active discussions on the measures necessary by the industry, government, academia, and civil society to promote vaccine R&D, which has low economic rationality and provide no incentives to the companies.

Due to the circumstances regarding the COVID-19 pandemic, this meeting was held online. 

2021 Advisory Board Working Group 5 (Titles omitted; in alphabetical order by last name)
Members:
 Ken J. Ishii (Professor, Division of Vaccine Science, Institute of Medical Science, The University of Tokyo/ Director, International Vaccine Design Center, Institute of Medical Science)
 Masayuki Imagawa (Chief Executive, Japan Vaccine Industry Association/ Vice President & Head, Japan Vaccine Business Unit, Takeda Pharmaceutical Co., Ltd.)
 Hiroshi Kasanuki (Specially Appointed Professor, Waseda University/ Advisor, Institute for Medical Regulatory Science, Waseda University)
 Kengo Sonoda (General Manager, Development Department, R&D Division, KM Biologics Co., Ltd.)
 Hideki Hasegawa (Director, Center for Influenza and Respiratory Virus Research, National Institute of Infectious Diseases)
 Yoshiharu Matsuura (Director, Center for Infectious Disease Education and Research (CiDER))
 Shinji Matsumoto (Chair, Vaccines Working Team, EFPIA Japan) 
 Isao Miyairi (Professor, Faculty of Pediatrics, Hamamatsu University School of Medicine)
 Yoshiaki Yamagishi (Associate Professor, Medical Center of Translational Research, Department of Medical Innovation, Osaka University)

Observer:
 Yasuhiro Araki (Director, Office of Vaccine and Blood Products, Pharmaceuticals and Medical Devices Agency)

MC/Moderator:
 Joji Sugawara (Manager, HGPI)

Opening Explanatory Introduction:
 Ryoji Noritake (CEO/Board Member, HGPI)